KR20240023709A - 사람 태반 관류액 세포를 포함하는 조성물, 상기 세포의 부분모집단 및 이의 용도 - Google Patents

사람 태반 관류액 세포를 포함하는 조성물, 상기 세포의 부분모집단 및 이의 용도 Download PDF

Info

Publication number
KR20240023709A
KR20240023709A KR1020247005001A KR20247005001A KR20240023709A KR 20240023709 A KR20240023709 A KR 20240023709A KR 1020247005001 A KR1020247005001 A KR 1020247005001A KR 20247005001 A KR20247005001 A KR 20247005001A KR 20240023709 A KR20240023709 A KR 20240023709A
Authority
KR
South Korea
Prior art keywords
cells
placental perfusate
composition
subject
human placental
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020247005001A
Other languages
English (en)
Korean (ko)
Inventor
조디 피. 거니
샤오구이 장
스테이시 허브
로버트 제이. 하리리
Original Assignee
안트로제네시스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안트로제네시스 코포레이션 filed Critical 안트로제네시스 코포레이션
Publication of KR20240023709A publication Critical patent/KR20240023709A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020247005001A 2013-11-15 2014-11-14 사람 태반 관류액 세포를 포함하는 조성물, 상기 세포의 부분모집단 및 이의 용도 Ceased KR20240023709A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201361905076P 2013-11-15 2013-11-15
US201361905077P 2013-11-15 2013-11-15
US61/905,076 2013-11-15
US61/905,077 2013-11-15
PCT/US2014/065665 WO2015073800A2 (en) 2013-11-15 2014-11-14 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses
KR1020217030425A KR20210121277A (ko) 2013-11-15 2014-11-14 사람 태반 관류액 세포를 포함하는 조성물, 상기 세포의 부분모집단 및 이의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217030425A Division KR20210121277A (ko) 2013-11-15 2014-11-14 사람 태반 관류액 세포를 포함하는 조성물, 상기 세포의 부분모집단 및 이의 용도

Publications (1)

Publication Number Publication Date
KR20240023709A true KR20240023709A (ko) 2024-02-22

Family

ID=53058264

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020247005001A Ceased KR20240023709A (ko) 2013-11-15 2014-11-14 사람 태반 관류액 세포를 포함하는 조성물, 상기 세포의 부분모집단 및 이의 용도
KR1020167015654A Ceased KR20160098244A (ko) 2013-11-15 2014-11-14 사람 태반 관류액 세포를 포함하는 조성물, 상기 세포의 부분모집단 및 이의 용도
KR1020217030425A Ceased KR20210121277A (ko) 2013-11-15 2014-11-14 사람 태반 관류액 세포를 포함하는 조성물, 상기 세포의 부분모집단 및 이의 용도

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020167015654A Ceased KR20160098244A (ko) 2013-11-15 2014-11-14 사람 태반 관류액 세포를 포함하는 조성물, 상기 세포의 부분모집단 및 이의 용도
KR1020217030425A Ceased KR20210121277A (ko) 2013-11-15 2014-11-14 사람 태반 관류액 세포를 포함하는 조성물, 상기 세포의 부분모집단 및 이의 용도

Country Status (11)

Country Link
US (2) US20160279171A1 (https=)
EP (1) EP3068432A4 (https=)
JP (4) JP2016537362A (https=)
KR (3) KR20240023709A (https=)
CN (2) CN105916521A (https=)
AU (3) AU2014348454A1 (https=)
CA (1) CA2930573C (https=)
MX (2) MX2016006270A (https=)
RU (1) RU2016123361A (https=)
WO (1) WO2015073800A2 (https=)
ZA (1) ZA201603270B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707491B2 (en) * 2016-11-11 2023-07-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods of treating neurodegenerative disorders
EP4417210A1 (en) * 2017-03-15 2024-08-21 Orca Biosystems, Inc. Compositions and methods for hematopoietic stem cell transplants
KR20210111244A (ko) * 2018-11-30 2021-09-10 셀룰래리티 인코포레이티드 태반-유래 동종이계 car-t 세포 및 이의 용도

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10001172A1 (de) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
DK1349918T3 (da) 2000-12-06 2014-11-10 Anthrogenesis Corp Fremgangsmåde til indsamling af stamceller fra moderkagen
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
EP2316919B1 (en) * 2001-02-14 2015-10-07 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
EP3246396B1 (en) * 2001-02-14 2020-01-29 Celularity, Inc. Renovation and repopulation of decellularized tissues and cadaveric organs by stem cells
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
WO2005094353A2 (en) * 2004-03-29 2005-10-13 Cytomatrix, Llc Methods for production of regulatory t cells and uses thereof
DK1957633T3 (en) * 2005-10-13 2014-03-17 Anthrogenesis Corp Immunomodulation USING PLACE SPEECH STEM CELLS
CN101389754A (zh) 2005-12-29 2009-03-18 人类起源公司 胎盘干细胞和第二来源干细胞的联合培养
PT2471904T (pt) 2005-12-29 2019-02-25 Celularity Inc População de células estaminais placentárias
NZ570614A (en) * 2006-01-23 2012-07-27 Athersys Inc Multipotent adult progenitor cell treatment of brain injuries and diseases
EP2023717B1 (en) * 2006-05-11 2016-04-13 Anthrogenesis Corporation Methods for collecting placenta cord blood stem cells
ZA200902233B (en) * 2006-10-23 2010-07-28 Anthrogenesis Corp Methods and compositions for treatment of bone defects with placental cell populations
AU2008216748A1 (en) * 2007-02-12 2008-08-21 Anthrogenesis Corporation Hepatocytes and chondrocytes from adherent placental stem cells; and CD34+, CD45- placental stem cell-enriched cell populations
EP2164953A4 (en) * 2007-06-18 2010-06-30 Childrens Hosp & Res Ct Oak METHOD OF ISOLATING STAIN AND PRECIPITATING CELLS FROM PLAZENTA
CA2700613C (en) * 2007-09-26 2022-09-20 Celgene Cellular Therapeutics Angiogenic cells from human placental perfusate
NZ599825A (en) 2007-09-28 2014-10-31 Anthrogenesis Corp Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
NZ592839A (en) 2008-11-21 2012-10-26 Anthrogenesis Corp Treatment of diseases, disorders or conditions of the lung using placental cells
WO2010105144A2 (en) * 2009-03-12 2010-09-16 University Of South Florida Method of disease-induced and receptor-mediated stem cell neuroprotection
US20100323446A1 (en) * 2009-06-05 2010-12-23 Jill Renee Barnett Method of collecting placental cells
US20120177618A1 (en) * 2009-07-14 2012-07-12 Massachusetts Institute Of Technology Hematopoietic stromal progenitor cells and uses thereof
US20110280849A1 (en) 2010-03-26 2011-11-17 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
LT2556145T (lt) * 2010-04-07 2016-11-10 Anthrogenesis Corporation Angiogenezė naudojant placentos kamienines ląsteles
ES2666746T3 (es) * 2010-07-13 2018-05-07 Anthrogenesis Corporation Métodos para generar linfocitos citolíticos naturales
MX2013006592A (es) * 2010-12-17 2014-02-06 Anthrogenesis Corp Tratamiento de lesion de la medula espinal y lesion traumatica de cerebro empleando celulas adherentes obtenidas del amnios.
KR20130128438A (ko) * 2010-12-17 2013-11-26 안트로제네시스 코포레이션 양막 유래 부착성 세포를 사용한, 면역-관련 질환 및 장애의 치료
US20120171180A1 (en) 2010-12-30 2012-07-05 Sascha Abramson Compositions comprising amnion derived adherent cells and platelet-rich plasma
WO2013055476A1 (en) 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
JP2015526088A (ja) * 2012-08-13 2015-09-10 アントフロゲネシス コーポレーション ナチュラルキラー細胞及びその使用
EP2909314B1 (en) 2012-10-19 2020-12-02 Celularity, Inc. Treatment of pain using amnion derived adherent cells

Also Published As

Publication number Publication date
US20160279171A1 (en) 2016-09-29
AU2022215291A9 (en) 2022-11-24
EP3068432A4 (en) 2017-04-19
CA2930573A1 (en) 2015-05-21
JP2016537362A (ja) 2016-12-01
AU2022215291A1 (en) 2022-09-01
WO2015073800A2 (en) 2015-05-21
ZA201603270B (en) 2022-09-28
CN105916521A (zh) 2016-08-31
JP2022020622A (ja) 2022-02-01
CN113679740A (zh) 2021-11-23
RU2016123361A (ru) 2017-12-20
JP2024016037A (ja) 2024-02-06
AU2020202182A1 (en) 2020-04-16
KR20210121277A (ko) 2021-10-07
AU2014348454A1 (en) 2016-06-02
JP2020019777A (ja) 2020-02-06
WO2015073800A8 (en) 2015-12-17
MX2016006270A (es) 2016-09-07
KR20160098244A (ko) 2016-08-18
US20190117705A1 (en) 2019-04-25
EP3068432A2 (en) 2016-09-21
CA2930573C (en) 2023-12-05
MX2021003799A (es) 2021-06-04
WO2015073800A3 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
JP7242761B2 (ja) キメラ抗原受容体及び他の受容体の発現に対するｔ細胞
Sanjuan-Pla et al. Platelet-biased stem cells reside at the apex of the haematopoietic stem-cell hierarchy
JP2024016037A (ja) ヒト胎盤灌流液細胞、その亜集団を含む組成物、およびそれらの使用
EP3749334B1 (en) Allogenic hematopoietic stem cell transplantation
Varmavuo et al. Blood graft composition after plerixafor injection in patients with NHL
WO2003012060A2 (en) Cellular compositions which facilitate engraftment of hematopoietic stem cells while minimizing the risk of gvhd
US20240408198A1 (en) Therapeutic compositions and methods for allogeneic hematopoietic stem cell transplantation
US20160151421A1 (en) Methods and compositions for long term hematopoietic repopulation
AU2018270407B2 (en) Selection and use of umbilical cord cell fractions suitable for transplantation
Basford et al. The cord blood separation league table: a comparison of the major clinical grade harvesting techniques for cord blood stem cells
Isidori et al. Positive selection and transplantation of autologous highly purified CD133+ stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging
CN119278262A (zh) 方法
US20140154219A1 (en) Methods and compositions for large-scale isolation of very small embryonic-like (vsel) stem cells
CN120187440A (zh) 用于造血干细胞移植的组合物和方法
Mizokami et al. Preferential expansion of human umbilical cord blood-derived CD34-positive cells on major histocompatibility complex-matched amnion-derived mesenchymal stem cells
JP2007105037A (ja) キメリズムを利用した幹細胞移植のための検査
JP2022533191A (ja) 拡大した幹細胞生成物を使用して、血液悪性腫瘍を有する患者の処置転帰を改善するための組成物および方法
HK40043608A (en) Allogenic hematopoietic stem cell transplantation
HK40043608B (en) Allogenic hematopoietic stem cell transplantation
Civin et al. Sustained, retransplantable, multilineage engraftment of highly
Tezcan et al. Graft engineering
BR112019024077B1 (pt) Método para preparar uma única unidade de sangue do cordão umbilical, e, artigo de fabricação

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T12 Administrative time limit extension not granted

Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T12-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

T12-X000 Administrative time limit extension not granted

St.27 status event code: U-3-3-T10-T12-oth-X000